Prestige Consumer Healthcare (NYSE:PBH) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Prestige Consumer Healthcare (NYSE:PBH) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $100.00 to $88.00. They now have a "buy" rating on the stock.
Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results
Prestige Consumer Healthcare (NYSE:PBH) had its price target lowered by analysts at Jefferies Financial Group Inc. from $75.00 to $71.00. They now have a "hold" rating on the stock.
Prestige Consumer Healthcare (NYSE:PBH) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $82.00 to $72.00. They now have an "outperform" rating on the stock.